Nurix
Nurix Therapeutics is looking for a Scientist to lead bioanalytical strategies for degrader antibody conjugates (DACs), focusing on LC‑MS/MS and hybrid assay approaches to quantify and characterize complex bioconjugates in vitro and in vivo. The role will involve method development, qualification, and execution to support pharmacokinetic, pharmacodynamic, and biotransformation studies, and will collaborate closely with DMPK, proteomics, pharmacology, and chemistry teams.
Headquarters
Brisbane, California, United States
Company Size
201-500 employees
Founded
2012
Nurix Therapeutics is a clinical-stage biopharmaceutical company developing medicines that harness targeted protein degradation to treat cancer and autoimmune diseases. Using a proprietary platform that combines small-molecule degraders and Degradation Activating Compounds (DACs) to engage E3 ubiquitin ligases and the ubiquitin–proteasome system, Nurix aims to selectively remove disease-causing proteins. The company advances multiple discovery and development programs and collaborates with partners to translate its platform into novel therapies. Their mission, "Medicines to Outmatch Disease," guides efforts to create differentiated, targeted treatments.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Nurix.
Nurix didn’t post a salary, so this is our estimate from similar listings.
33% above the average for this role
Nurix Therapeutics: Why This Company Could Double In Value? (NASDAQ:NRIX)
1 month ago